Other Earnings and Cash Flow Stats:
AMGEN INC ( AMGN ) Net Income TTM ($MM) is 4230.00
AMGEN INC ( AMGN ) Operating Income TTM ($MM) is 6218.00
AMGEN INC ( AMGN ) Owners' Earnings Annual ($MM) is 0.00
AMGEN INC ( AMGN ) Current Price to Owners' Earnings ratio is 0.00
AMGEN INC ( AMGN ) EBITDA TTM ($MM) is 11793.00
AMGEN INC ( AMGN ) EBITDA Margin is 38.45%
Capital Allocation:
AMGEN INC ( AMGN ) has paid 9.00 dividends per share and bought back -4.0 million shares in the past 12 months
AMGEN INC ( AMGN ) has reduced its debt by 70.0 million USD in the last 12 months
Capital Structure:
AMGEN INC ( AMGN ) Interest-bearing Debt ($MM) as of last quarter is 60398
AMGEN INC ( AMGN ) Annual Working Capital Investments ($MM) are 439
AMGEN INC ( AMGN ) Book Value ($MM) as of last quarter is 7527
AMGEN INC ( AMGN ) Debt/Capital as of last quarter is 802%
Other Balance Sheet Stats:
AMGEN INC ( AMGN ) has 9011 million in cash on hand as of last quarter
AMGEN INC ( AMGN ) has 20312 million of liabilities due within 12 months, and long term debt 60398 as of last quarter
AMGEN INC ( AMGN ) has 542 common shares outstanding as of last quarter
AMGEN INC ( AMGN ) has 0 million USD of preferred stock value
Academic Scores:
AMGEN INC ( AMGN ) Altman Z-Score is 1.33 as of last quarter
AMGEN INC ( AMGN ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
AMGEN INC ( AMGN ) largest shareholder is owning shares at 0.00 ($MM) value
Grygiel Nancy A.(an insider) Sold 2117 shares of AMGEN INC ( AMGN ) for the amount of $662801.58 on 2024-05-03
0.25% of AMGEN INC ( AMGN ) is held by insiders, and 81.90% is held by institutions
AMGEN INC ( AMGN ) went public on 1983-06-17
Other AMGEN INC ( AMGN ) financial metrics:
FCF:6283.00
Unlevered Free Cash Flow:0.00
EPS:20.89
Operating Margin:24.07
Gross Profit Margin:61.07
Div. Payout Ratio%:115.32
Div. Growth YoY%:8.04
Equity Return%:150.39
Beta:0.52
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AMGEN INC ( AMGN ) :
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
DISCLAIMER
This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.